Working… Menu

Milnacipran for Chronic Pain in Knee Osteoarthritis (KOA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01510457
Recruitment Status : Completed
First Posted : January 16, 2012
Results First Posted : January 22, 2015
Last Update Posted : June 22, 2015
Forest Laboratories
Information provided by (Responsible Party):
Dr. Norman Harden, Shirley Ryan AbilityLab

Brief Summary:
The patients are asked to take part in this study because you have chronic pain as a result of knee osteoarthritis. This study is done to investigate the pain relieving effects of the study drug Savella (milnacipran HCl) for people who experience chronic osteoarthritis pain. The purpose of this research is to look at how the study drug can be used to benefit people who experience osteoarthritis knee pain. This is a phase IV study done to study the safety and effectiveness of the drug. At this point the drug is already approved by the Food and Drug Administration for people with fibromyalgia but it has not yet been approved for people with knee osteoarthritis.

Condition or disease Intervention/treatment Phase
Knee Osteoarthritis Degenerative Joint Disease Chronic Pain Drug: Milnacipran Drug: Placebo Phase 4

Detailed Description:

If you are in this study, you will be placed in one of two study groups: one group will receive the study drug and one will receive a placebo. You will be assigned a study group by chance using a process similar to the flip of a coin.

At the first visit (week one) we will review and sign the informed consent, obtain your medical health history, and conduct a brief physical exam. You will also complete several questionnaires about your pain. You will be assessed for your eligibility to participate in this study. If you are eligible, we will conduct some physical and sensory tests and collect a blood sample. The physical tests include a stair climb, 6-minute treadmill test and a 1-minute sit to stand test. The sensory tests allow us to understand your perception of various stimuli such as vibration, light touch, pinprick, heat, cold, hot pain, and cold pain. At the end of the first visit you will be given an electronic diary to record your pain throughout the study. We will also ask you to wear a device in a T-shirt, similar to an accelerometer, that will be used to record your sleep quality and physical activity for 2 days.

At the second (week two) and third visits (week nine) you will be asked to complete the same questionnaires, physical and sensory tests as during the first visit. You will also have to wear the t-shirt with the device for 2 days after each visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Milnacipran for the Pain, Sensory Sensitization and Mood Changes in Knee Osteoarthritis
Study Start Date : November 2010
Actual Primary Completion Date : October 2013
Actual Study Completion Date : October 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Sugar Pill
BID placebo
Drug: Placebo
Subjects will receive identical placebo pills and dosing schedule as that of participants receiving active study medication.
Other Name: "Sugar Pill"

Experimental: Milnacipran
Uptitration from 10mg to 50mg BID Milnacipran
Drug: Milnacipran
Total target dose of 200 mg/day. Subjects will titrate-up according to the following schedule: 25 mg/d (2 pills, 2 days), 50mg mg/d (4 pills, 2 days), 100mg/d (2 pills, 3 days), 150 mg/d (3 pills, 4 days), and steady state is reached once the study participant ingests 200 mg/d(4 pills). The steady state is maintained for 44 days (approx. 6 weeks). If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 100 mg/day at the discretion of the PI. Subjects unable to tolerate 100 mg/day will be discontinued from the study. A 2-week down-titration will be used.
Other Name: Savella (milnacipran HCL) Tablets

Primary Outcome Measures :
  1. McGill Pain Questionnaire - Short Form [ Time Frame: Collected at 2 visits over 11 weeks: Visit 1 and Visit 3. ]
    The MPQ-SF is a well-validated pain measure that permits separation of the sensory and affective components of pain, which are added together to compute a total score. The scale ranges from 0-45 (0=no pain, 45=the most pain).

  2. PamSys Actigraph Data [ Time Frame: 48 hours after visit 3 ]
    We used a body worn sensor (PAMSys™, Biosensics, LLC, MA)(25-27) embedded in a comfortable t-shirt at the sternal level. Participants wore the PAMSys after the visit for 48 hours. The device provides values related to subjects spontaneous physical activity including percentage of time standing and walking. These variables provide different indexes of participants' level of activity and activity organization, and were reported by subjects with KOA pain as relevant.

  3. Pain Anxiety Symptoms Scale (PASS) [ Time Frame: Collected at 2 visits over 11 weeks: Visit 1 and Visit 3. ]
    Anxiety scores were collected at least two data points. The Pain Anxiety Symptoms Scale (PASS) is a scale from 0 - 100, where 0 = no anxiety and 100 = the most anxiety.

  4. Pain Disability Index (PDI) [ Time Frame: Collected at 2 visits over 11 weeks: Visit 1 and Visit 3. ]
    The PDI is a seven-item, validated instrument that assesses perceived disability in seven key life areas. It provides a total disability score, and is an indirect measure of self efficacy. The Pain Disability Scale is a scale from 0 - 70, where 0 = no Disability and 70 = the most Disability.

  5. Center for Epidemiological Studies Depression Scale CESD-10 (CES-D 10) [ Time Frame: Collected at 2 visits over 11 weeks: Visit 1 and Visit 3. ]
    The CES-D 10 is a 10-item questionnaire that has been validated for the assessment of depressive symptomatology. The Depression Scale is a scale with a sum score from 0 - 30, where 0 = no Depression and 30 = the most Depression.

  6. Pain Visual Analogue Scale [ Time Frame: Collected at 2 visits over 11 weeks: Visit 1 and Visit 3. ]
    Pain Visual Analogue Scale from 0-100 (0= no pain, and 100= most pain).

Secondary Outcome Measures :
  1. Daily Diary Entries With Pain, Fatigue and Functioning Scores Three Times a Day [ Time Frame: electronic diary entries with pain, fatigue and functioning scores were completed three times a day during week 1 and week 11 ]
    Averages of daily diary outcomes were taken over the first and last week of the trial (week 1 and week 11) to compare pre and post treatment. diary was filled out 3 times a day and asked subjects to rate pain at rest, pain when walking, and fatigue on a scale 0-10 (0=none, and 10=the worst)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Knee pain and osteophytes on radiographs OR
  • Knee pain plus patient age of 40 years or older, morning stiffness lasting 30 minutes or less, and crepitus (cracking sound) during motion
  • Experiences chronic pain for 6 months or longer
  • Average pain rating of worse knee is equal to 4 or greater on a 0-10 scale
  • If female, is not pregnant or breast feeding, and not currently attempting to conceive; if of childbearing potential, use of a highly effective method of birth control (as determined by Pl)
  • Able to walk at least ½ a city block a day, and agrees to try and slowly increase that over the course of study
  • Able to read and speak English and provide informed consent
  • Able to understand and comply with all data collection methodology including electronic diary
  • Subject agrees to 1) continue their stable drug regimen with no changes during the course of study, 2) only use Tylenol 325 mg of tablets (a maximum of 8 tablets a day) for breakthrough pain, and 3) not use Tylenol or any other pain medicines 12 hours before testing.

Exclusion Criteria:

  • Subject takes SNRIs (Savella, Cymbalta, Venlafaxine) or other neuroamine re-uptake blockers for mood disorders
  • Subject is allergic to SSRIs, SNRIs, or milnacipran
  • Subject has severe or untreated psychiatric disturbance (e.g. mania, depression, anxiety, substance dependence)
  • Subject is medicated with 'triptans, MAOIs, SSRIs, other SNRIs, tricyclic or heterocyclic antidepressants, lithium, epinephrine, norepinephrine, clonidine or digoxin during the trial
  • Subject has a clinical diagnosis of fibromyalgia
  • Subject has severe ongoing or unaddressed medical conditions (e.g. Renal or Hepatic disease [creatinine>1.5 ml/dl; AST or ALT> 3x normal limit], uncontrolled hypertension, severe cardiac rate or rhythm disorders, rheumatologic disease (e.g. polymyalgia rheumatica), narrow angle glaucoma, hyponatremia, clotting disorders, uncontrolled seizure disorder or urinary retention)
  • Subject has cardiac implants
  • Subject has a knee replacement
  • Subject plans to start new pain treatments or therapies during the study (e.g. new pain medication, injections, PT, surgery)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01510457

Sponsors and Collaborators
Dr. Norman Harden
Forest Laboratories
Layout table for investigator information
Principal Investigator: Norman Harden, MD Center for Pain Studies, Rehabilitation Institute of Chicago

Layout table for additonal information
Responsible Party: Dr. Norman Harden, Principal Investigator, Shirley Ryan AbilityLab Identifier: NCT01510457     History of Changes
Other Study ID Numbers: SAV-MD-23
First Posted: January 16, 2012    Key Record Dates
Results First Posted: January 22, 2015
Last Update Posted: June 22, 2015
Last Verified: May 2015
Keywords provided by Dr. Norman Harden, Shirley Ryan AbilityLab:
Knee Osteoarthritis
Degenerative Joint Disease
Chronic Pain
Knee Pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Joint Diseases
Chronic Pain
Musculoskeletal Diseases
Rheumatic Diseases
Neurologic Manifestations
Signs and Symptoms
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Antidepressive Agents
Psychotropic Drugs